San Francisco Bay Area biotech stories.
Tuesday, September 11, 2012
Andrew Gengos out, John Walker in as Neuraltus CEO
Andrew Gengos, who led Neuraltus Pharmaceuticals Inc. into a Phase II trial of its experimental treatment for Lou Gehrig's disease, has left the company.
Veteran Bay Area biotech executive
, Neuraltus' chairman, took over Aug. 15 as interim CEO, according to a company telephone message.
Share to Twitter
Share to Facebook
Share to Pinterest
Post a Comment
Post Comments (Atom)